Overview

Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery

Status:
Completed
Trial end date:
2015-04-23
Target enrollment:
Participant gender:
Summary
A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.
Phase:
Phase 2
Details
Lead Sponsor:
Diane Cantella
Matthew R Quigley
Collaborator:
DUSA Pharmaceuticals, Inc.
Treatments:
Aminolevulinic Acid